Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is MPM Bioimpact LLC's 6th Largest Position

MPM Bioimpact LLC boosted its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 19.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 589,579 shares of the company's stock after purchasing an additional 96,856 shares during the period. Mirum Pharmaceuticals makes up about 3.5% of MPM Bioimpact LLC's portfolio, making the stock its 6th largest holding. MPM Bioimpact LLC owned 1.23% of Mirum Pharmaceuticals worth $24,379,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. increased its position in Mirum Pharmaceuticals by 25.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company's stock worth $6,021,000 after buying an additional 29,545 shares during the last quarter. AlphaQuest LLC boosted its holdings in Mirum Pharmaceuticals by 969.6% during the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after purchasing an additional 1,658 shares in the last quarter. Golden State Equity Partners boosted its holdings in Mirum Pharmaceuticals by 1,390.8% during the fourth quarter. Golden State Equity Partners now owns 19,380 shares of the company's stock valued at $801,000 after purchasing an additional 18,080 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $277,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $413,000.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on MIRM shares. JMP Securities boosted their price objective on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research report on Friday, May 9th. Raymond James reaffirmed a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday. HC Wainwright increased their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Finally, Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. Ten analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $60.64.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, Director Patrick J. Heron purchased 1,335 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of $45.57 per share, for a total transaction of $60,835.95. Following the completion of the transaction, the director now owns 163,643 shares of the company's stock, valued at approximately $7,457,211.51. This trade represents a 0.82% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Christopher Peetz sold 27,279 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the transaction, the chief executive officer now owns 138,641 shares in the company, valued at $6,129,318.61. This trade represents a 16.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 92,764 shares of company stock valued at $4,109,161 over the last 90 days. 14.36% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Trading Down 0.6%

Shares of Mirum Pharmaceuticals stock traded down $0.27 during trading on Friday, reaching $45.01. The company's stock had a trading volume of 219,847 shares, compared to its average volume of 523,969. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -22.28 and a beta of 0.95. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The firm's 50-day moving average is $42.96 and its two-hundred day moving average is $44.43. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.83 and a 52-week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. The firm had revenue of $111.59 million for the quarter, compared to the consensus estimate of $98.47 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business's quarterly revenue was up 61.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.54) EPS. On average, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.